BOSTON, Sept. 4, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that it had received a letter from the New York Stock Exchange ("NYSE") on September 3, 2024 stating that because Ginkgo's Class A common stock had a closing bid price at or above $1.00 on the last day of August and the Company's 30-day trading average closed above $1.00, Ginkgo had regained compliance with Section 802.01C of the NYSE Listed Company Manual.

BOSTON, Aug. 30, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Chief Financial Officer, Mark Dmytruk, is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6 at 11:30 a.m. ET.

Further details, a webcast link, and a replay of the fireside chat will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force 

BOSTON, Aug. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET

BOSTON, Aug. 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock in a range of not less than one-for-twenty (1:20) and not more than one-for-forty (1:40), with the final ratio to be determined by the Board of Directors. Shareholders will also vote to approve Ginkgo's Amended and Restated Certificate of Incorporation, which has been updated to permit officer exculpation and remove provisions related to our merger with Soaring Eagle Acquisition Corp. and our domestication process, which are no longer relevant to our business.

Presentation and Q&A session scheduled for post-market on Thursday, August 8, 2024

BOSTON, Aug. 1, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, beginning at 5:30 p.m. ET.

NEW YORK, July 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on behalf of the company's shareholders. The investigation seeks to determine whether Ginkgo's directors breached their fiduciary duties in connection with recent corporate actions.

If you are a shareholder of Ginkgo Bioworks Holdings, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfirm.com/ginkgo-bioworks-holdings-inc/

Syngenta will leverage Ginkgo's Ag Biologicals capabilities to optimize secondary metabolite production for a pioneering biological solution

BASEL, Switzerland and BOSTON, July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology.

BOSTON, May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May.

TD Cowen's 2nd Annual Sustainability Week: Ginkgo's Senior Director of Policy and Partnerships, Ryan Morhard, will participate in the virtual Sustainable API Manufacturing panel at 4:25 pm ET on May 22, 2024.Leerink Partners Healthcare Crossroads Conference: Ginkgo's Chief Business Officer, Ena Cratsenburg, will host a fireside chat at 10:40 am CT (11:40 am ET) on May 30, 2024.

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy

TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.

Ginkgo's Class A Common Stock continues to trade on the NYSE

BOSTON, May 13, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that it received a notice on May 7, 2024 from the New York Stock Exchange ("NYSE") informing the Company that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's Class A common stock was less than $1 per share over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company's Class A common stock from the NYSE.